Eisai et Henlius concluent un accord de licence commerciale exclusive pour l'anticorps anti-PD-1 serplulimab au Japon

Henlius China

View original content:https://www.prnewswire.com/news-releases/eisai-et-henlius-concluent-un-accord-de-licence-commerciale-exclusive-pour-lanticorps-anti-pd-1-serplulimab-au-japon-302680845.html